Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer
Introducing immunotherapy within the first 30 days of chemotherapy initiation significantly increases survival in patients with stage IV NSCLC.
Authors
- Takefumi Komiya (ORCID: https://orcid.org/0000-0002-6484-2210)
- Jorge Raúl Vázquez-Urrutia (ORCID: https://orcid.org/0000-0001-9211-8572)
- Junjia Zhu (ORCID: https://orcid.org/0000-0003-1311-3752)
- Max Greenberg (ORCID: https://orcid.org/0000-0003-2133-7908)
- Shinkichi Takamori (ORCID: https://orcid.org/0000-0001-8175-6798)
Institutions
- Pennsylvania State University (US)
- Oita University (JP)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- World Journal of Oncology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.14740/wjon1924
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Gilead Sciences
- Novocure